Need a mesothelioma lawyer? We will fight for you!
› $150,000,000 verdict in personal injury case
More than 40 drug development programs have transdermal systems, or drug patches, under development for either initial approval or expanded indications, according to Pharma Live. But can consumers trust their safety record?
Canadian pharmaceutical company Janssen-Ortho, Inc. in cooperation with Health Canada has issued a press release updating information on the average daily release rates of contraceptive hormones from the EVRA Transdermal Contraceptive System (patch) that is marketed in Canada and approved for use for the prevention of pregnancy. EVRA is bioequivalent to Ortho Evra, the birth control patch that is marketed in the United States.
A new provision in the proposed budget signed by President Barack Obama last week could help significantly reduce the cost of birth control for young women by allowing pharmaceutical companies to reinstate discounts on contraceptives that they had previously offered to family planning clinics.
A new program in Wayne County, Michigan, is giving financially strapped women access to free family planning services, health care and birth control. However, women should be advised to consider their birth control options even if they come at no cost.
Johnson & Johnson, the makers of the Ortho Evra contraceptive patch for women, has agreed to settle lawsuits filed by Canadian women who suffered from blood clots, heart attacks or strokes after using the patch. The drug maker avoided trial by spending more than $68 million to settle similar claims by women in the United States, according to Bloomberg.
![[ Beasley Allen Law Firm Logo ]](http://www.orthoevra-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}